(Total Views: 654)
Posted On: 05/22/2022 9:39:06 AM
Post# of 148925
For anyone interested, I'm leaving it as is. Read it or ignore it.
Slow down and Relax. Time is Necessary for the Game to be Played Out
Hopefully, you will know by end of this, that CytoDyn is on target. What happened in the past, had to have happened to put us where we are today.
Things need to take place on their own time. No boxes. No enclosures. Things are becoming OBVIOUS and require no Press Release. We can use our heads to piece together clues.
It all comes down to one thing: the molecule, the fact that it works and is harmless. The world may collapse around us, but there stands yet a solution and it will not be unapproved indefinitely.
CytoDyn is on course in the works necessary to bring it to approval.
Recknor was supposed to give us the NASH 700 Database lock in January. I read that the NASH 700 trial won't be closed until late July 2022. (I'm not sure if this is true, but, for the purposes of this discussion, let's say that it is). How could it be that trial closes in late July?, when these results are slated to be presented on June 25. I painted a picture that NASH 700 may double the results of NASH 350 which themselves were stellar. I stated NASH 700 could be close to being twice as good, even eradicating full blown NASH from NAS 8 to NAS 0. I still stand by these.
I watched the conference last night, "Let's Smash Nash!" Nothing burger. But they were primarily using a FIB score, (not cT1 nor PDFF). The FIB-4 scoring system uses a combination of patient age, platelet count, AST and ALT - all tests available to the primary care physician. The scoring system creates a score of less than 1.45 has a negative predictive value of over 90% for advanced liver fibrosis of multiple etiologies. A score of more than 3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.
They also used a LSM, Liver Stiffness Measure done by transient elastography, FibroScan. A LSM greater than 12.0 kPa is high risk. Then they take it to liver biopsy.
Mazen Noureddin, MD, Director, Cedars-Sinai Fatty Liver Program , said in the conference, "Newly available, non-invasive, diagnostic procedures are expanding the types of healthcare professionals who can expect to care for patients with NAFLD beyond hepatologists and gastroenterologists."
He probably was referring to MRI based cT1 and PDFF, where biopsy really is not needed, but not yet proven.
If it is true that the NASH 700 trial will be closed late July 2022, what is Recknor doing with the data he has uncovered? Why didn't he just do the database lock back in January? New patients weren't being added. I don't believe they continued dosing LL to those patients to see if the fibrosis would be completely eradicated. Is it possible they did? Anyway, on June 25, we should learn a lot more.
It is coming together in its necessary time.
The IP on LL patent is no longer at any risk thanks to recent 8k. The aggregated safety data to be accounted for about June 15. Later, when due course judgement is made over Amarex, that $6.5 million goes back on CytoDyn balance sheet in the cash column. LL was administered to all surviving mTNBC patients after the trial was closed in November, yes, as per drD, (Thank you). Granted, those patients were sick, very sick. Much sicker than Gilead's Trodelvy's patients. But we beat them 12.5 to 12 month even with very sick individuals. But the clock kept going, even though the game was over. We did not stop playing. We kept giving it as per schedule. The result of that should also be revealed in early June.
Do you need a Press Release?
Monkey Pox? Ha, what will that bring? How bad do they want this to get? How bad will they permit this to get? Do they want the whole world to collapse? Maybe it will, but upon them, the instigators.
This molecule has fantastical power in the way it modulates our Adaptive and Innate Immunity which is at the heart of and the manner by which, we stay alive in this world of bacteria, virus', fungi and parasites. It is the missing link to defeating and overcoming a multitude of disease and pathology. As such, it is fantastically shunned, resisted and hated by those who depend on propagation of disease as source for their livelihood; namely, Big Pharma, Big Media, Big Money, until that day comes when their own manipulations put them all 6' under.
Amarex shall come to pass and the revelations it shall bring will illuminate.
I feel like the share price has come down to this price for one reason. To graft in a whole multitude, as many as are able, to acquire a portion of this company to have and to hold for themselves and their progeny, because CytoDyn shall escape the inevitable dread. Traders may come and go, but longs stick around by their understanding.
Partnership? Plain as day. I've written enough as to why. Scott Kelly said it plainly. Refer to last conference call and read his closing words.
I don't know the day of approval, but it certainly shall come.
The world is tripping and falling while we do the opposite. We are surrounded by enemies who don't know their ass from their elbow. What is seen as fair, really is unfair. What is seen as right, really is wrong. That which is wrong is made to seem that it is right.
We had anticipated. I am just as guilty as anyone else. I bet hugely under $3, but now I own at $2. Regardless, I thought I had the timing right. I was wrong on the timing then but, I hold and wait. I know the time shall come. It's not "if", it's "when". Therefore, I hold and wait.
Now, it has become clear. We aren't left with too much more we can count on. NASH 700, mTNBC, HIV, Amarex. Company is on a shoe string budget. Money just trickling in to keep us afloat. Can't go too much further without something massive. We have something massive and we have been playing possum, (thanks sean007).
Slow down and relax.
Slow down and Relax. Time is Necessary for the Game to be Played Out
Hopefully, you will know by end of this, that CytoDyn is on target. What happened in the past, had to have happened to put us where we are today.
Things need to take place on their own time. No boxes. No enclosures. Things are becoming OBVIOUS and require no Press Release. We can use our heads to piece together clues.
It all comes down to one thing: the molecule, the fact that it works and is harmless. The world may collapse around us, but there stands yet a solution and it will not be unapproved indefinitely.
CytoDyn is on course in the works necessary to bring it to approval.
Recknor was supposed to give us the NASH 700 Database lock in January. I read that the NASH 700 trial won't be closed until late July 2022. (I'm not sure if this is true, but, for the purposes of this discussion, let's say that it is). How could it be that trial closes in late July?, when these results are slated to be presented on June 25. I painted a picture that NASH 700 may double the results of NASH 350 which themselves were stellar. I stated NASH 700 could be close to being twice as good, even eradicating full blown NASH from NAS 8 to NAS 0. I still stand by these.
I watched the conference last night, "Let's Smash Nash!" Nothing burger. But they were primarily using a FIB score, (not cT1 nor PDFF). The FIB-4 scoring system uses a combination of patient age, platelet count, AST and ALT - all tests available to the primary care physician. The scoring system creates a score of less than 1.45 has a negative predictive value of over 90% for advanced liver fibrosis of multiple etiologies. A score of more than 3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.
They also used a LSM, Liver Stiffness Measure done by transient elastography, FibroScan. A LSM greater than 12.0 kPa is high risk. Then they take it to liver biopsy.
Mazen Noureddin, MD, Director, Cedars-Sinai Fatty Liver Program , said in the conference, "Newly available, non-invasive, diagnostic procedures are expanding the types of healthcare professionals who can expect to care for patients with NAFLD beyond hepatologists and gastroenterologists."
He probably was referring to MRI based cT1 and PDFF, where biopsy really is not needed, but not yet proven.
If it is true that the NASH 700 trial will be closed late July 2022, what is Recknor doing with the data he has uncovered? Why didn't he just do the database lock back in January? New patients weren't being added. I don't believe they continued dosing LL to those patients to see if the fibrosis would be completely eradicated. Is it possible they did? Anyway, on June 25, we should learn a lot more.
It is coming together in its necessary time.
The IP on LL patent is no longer at any risk thanks to recent 8k. The aggregated safety data to be accounted for about June 15. Later, when due course judgement is made over Amarex, that $6.5 million goes back on CytoDyn balance sheet in the cash column. LL was administered to all surviving mTNBC patients after the trial was closed in November, yes, as per drD, (Thank you). Granted, those patients were sick, very sick. Much sicker than Gilead's Trodelvy's patients. But we beat them 12.5 to 12 month even with very sick individuals. But the clock kept going, even though the game was over. We did not stop playing. We kept giving it as per schedule. The result of that should also be revealed in early June.
Do you need a Press Release?
Monkey Pox? Ha, what will that bring? How bad do they want this to get? How bad will they permit this to get? Do they want the whole world to collapse? Maybe it will, but upon them, the instigators.
This molecule has fantastical power in the way it modulates our Adaptive and Innate Immunity which is at the heart of and the manner by which, we stay alive in this world of bacteria, virus', fungi and parasites. It is the missing link to defeating and overcoming a multitude of disease and pathology. As such, it is fantastically shunned, resisted and hated by those who depend on propagation of disease as source for their livelihood; namely, Big Pharma, Big Media, Big Money, until that day comes when their own manipulations put them all 6' under.
Amarex shall come to pass and the revelations it shall bring will illuminate.
I feel like the share price has come down to this price for one reason. To graft in a whole multitude, as many as are able, to acquire a portion of this company to have and to hold for themselves and their progeny, because CytoDyn shall escape the inevitable dread. Traders may come and go, but longs stick around by their understanding.
Partnership? Plain as day. I've written enough as to why. Scott Kelly said it plainly. Refer to last conference call and read his closing words.
I don't know the day of approval, but it certainly shall come.
The world is tripping and falling while we do the opposite. We are surrounded by enemies who don't know their ass from their elbow. What is seen as fair, really is unfair. What is seen as right, really is wrong. That which is wrong is made to seem that it is right.
We had anticipated. I am just as guilty as anyone else. I bet hugely under $3, but now I own at $2. Regardless, I thought I had the timing right. I was wrong on the timing then but, I hold and wait. I know the time shall come. It's not "if", it's "when". Therefore, I hold and wait.
Now, it has become clear. We aren't left with too much more we can count on. NASH 700, mTNBC, HIV, Amarex. Company is on a shoe string budget. Money just trickling in to keep us afloat. Can't go too much further without something massive. We have something massive and we have been playing possum, (thanks sean007).
Slow down and relax.
(12)
(1)Scroll down for more posts ▼
